TD Cowen lowered the firm’s price target on BioNTech (BNTX) to $122 from $132 and keeps a Hold rating on the shares. The firm noted ...
John Newman, an analyst from Canaccord Genuity, maintained the Buy rating on BioNTech SE (BNTX – Research Report). The associated price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback